Compare Kimberly Clark Corp (KMB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs 10X Genomics Inc — how do they compare? Kimberly Clark Corp trades at $108.56 (market cap $36.01B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Kimberly Clark Corp is far larger — about 6.6× 10X Genomics Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| KMB | TXG | |
|---|---|---|
Market Cap | $36.01B | $5.48B |
Sector | Consumer Staples | Health |
52-Week High | $136.77 | $45.80 |
52-Week Low | $93.05 | $11.34 |
Enterprise Value | $42.55B | $5.02B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.05, down 0.28% on the day, with a neutral technical signal. The stock shows strong profitability with a net income margin of 12.8% and has beaten earnings estimates for the last three quarters. Recent news highlights its status as a Dividend King and strategic moves like the Arbex joint venture. Cash flow trends indicate operational strength despite recent net outflows.
KMB offers a stable investment with a solid dividend yield and consistent earnings beats, but faces risks from high payout ratios and competitive pressures. Analyst consensus is mixed with a hold-heavy rating, though the $115.33 price target suggests modest upside. Revenue declines in 2025 warrant monitoring for sustained growth.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
